Skip to Content

Teleflex Inc TFX

Morningstar Rating
$224.79 −1.25 (0.55%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Teleflex Earnings: Maintaining Fair Value as Solid Year-End Results Set Stage for Normalized Growth

No-moat Teleflex posted solid fourth-quarter results in line with our expectations. We are maintaining our $211 fair value estimate. With inflation, supply chain challenges, and utilization disruptions winding down, we believe Teleflex’s broad portfolio can support a stable longer-term growth trend. Despite the 5% post-earnings price drop, we still think the stock is overvalued.

Price vs Fair Value

TFX is trading at a 7% premium.
Price
$224.79
Fair Value
$481.00
Uncertainty
Medium
1-Star Price
$225.24
5-Star Price
$217.30
Economic Moat
Kwcd
Capital Allocation
Xdhcy

Bulls Say, Bears Say

Bulls

UroLift provides a meaningful clinical benefit in an area of unmet need. The market opportunity is substantial, and the product could be a home-run acquisition if sales continue to grow at its current pace.

Bears

Historical acquisitions have not materially improved the company's return on capital, and the verdict is still out on management's capital allocation skill.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TFX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$226.04
Day Range
$224.45227.45
52-Week Range
$177.63276.43
Bid/Ask
$89.90 / $254.00
Market Cap
$10.58 Bil
Volume/Avg
302,490 / 272,487

Key Statistics

Price/Earnings (Normalized)
16.46
Price/Sales
3.57
Dividend Yield (Trailing)
0.61%
Dividend Yield (Forward)
0.61%
Total Yield
0.61%

Company Profile

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2022 sales), interventional (16%), anesthesia (14%), surgical (14%), interventional urology (12%), original-equipment manufacturing (10%), and all other (10%). Geographic exposure for the business is primarily in the U.S., which accounts for 60% of revenue, with international markets making up the remainder.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Mid Core
Total Number of Employees
14,500

Competitors

Valuation

Metric
TFX
BDX
BSX
Price/Earnings (Normalized)
16.4620.0632.68
Price/Book Value
2.382.735.09
Price/Sales
3.573.566.88
Price/Cash Flow
17.0621.2829.94
Price/Earnings
TFX
BDX
BSX

Financial Strength

Metric
TFX
BDX
BSX
Quick Ratio
1.100.460.63
Current Ratio
2.321.081.32
Interest Coverage
5.954.178.41
Quick Ratio
TFX
BDX
BSX

Profitability

Metric
TFX
BDX
BSX
Return on Assets (Normalized)
5.96%3.40%8.92%
Return on Equity (Normalized)
10.10%7.05%16.33%
Return on Invested Capital (Normalized)
7.98%5.04%11.43%
Return on Assets
TFX
BDX
BSX
See how this stock stacks up to its competitors with Morningstar Investor

Medical Instruments & Supplies Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ISRG
Intuitive Surgical IncWzkqm$136.2 Bil
BDX
Becton Dickinson & CoDxhkscr$69.1 Bil
ALC
Alcon IncQgcmbk$41.8 Bil
CLPBY
Coloplast A/S ADRSllc$30.0 Bil
WST
West Pharmaceutical Services IncQsfm$26.2 Bil
RMD
ResMed IncPwhvyh$25.6 Bil
BAX
Baxter International IncMyrwfxn$21.1 Bil
COO
The Cooper Companies IncNpsvcrk$18.8 Bil
HOLX
Hologic IncXtlhgy$17.4 Bil

Sponsor Center